Enlivex: Down on upsized bought deal offering

Enlivex

10/02/2021 11:38

** U.S.-listed shares of Israel-based drug developer Enlivex
Therapeutics Ltd  ENLV.O  down 9.3% at $21.75 premarket
    * Co on Tuesday after market hours increased size of its
previously announced $10 mln bought deal offering  urn:newsml:reuters.com:*:nGNX2G3zdb
    ** Co says underwriters have agreed to purchase 2,296,107
common shares at $20 per share for gross proceeds of ~$46 mln
    ** Shares on offer represent nearly 17% of co's outstanding
stock - Refinitiv data
    ** Net proceeds will be used to fund co's clinical,
regulatory, manufacturing and research and development
activities and potential acquisitions among other things
    ** Offering is expected to close on or about Feb 12
    ** ENLV has granted to underwriter a 30-day option to
purchase up to 344,416 additional ordinary shares at public
offering price
    ** H.C. Wainwright & Co. is sole book-running manager for
the offering
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))